Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Old API Wind-down Ltd - Ordinary Shares ARLZQ

"Old API Wind-down Ltd, formerly Aralez Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in the acquisition, development, and commercialization of products primarily in cardiovascular, pain management and other specialty areas. Its key products include Fiorinal, Proferrin, Fibricor, Uracyst and Neovisc, Cambia and other marketed products. The company currently operates in two geographical markets, the United States and Canada. The firm generates most of its reven


OTCPK:ARLZQ - Post by User

Post by kuatoliveson Nov 07, 2016 8:33pm
134 Views
Post# 25434769

Understated Revenue?

Understated Revenue?

We seem to be missing 8 million dollars here:

 

Revenue for first 9 months of 2016 = $34.24M

Q4 estimated revenue from Toprol = $22.5M  (This is calculated as 90M for the year / 4 quarters) = 22.5M

 

Assuming no growth in Q4 (or seasonality (is there any?) offsetting the growth), that gives us:


34.2 (Revenue first 9 months) 

+ 22.5 (Toprol XL Q4 Estimated)

———————————

 = 56.75M + Q4 "other revenue"

 

 

The last quarter was just 13.5, so if other Q4 revenue is the same (assuming no growth), this puts us at $70 million for 2016, not 62 (at the high end).  (That is, 56.75 + 13.5M = 70.25M)

 

Yet their top end guidance was 62M. Did they understate their 2016 net revenue guidance by 8M?
Where did the rest of the revenue go? Is Toprol seriously seasonal or something?

Help me out here....

 

<< Previous
Bullboard Posts
Next >>